Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:18:04 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



News for U:OCGN from 2023-05-04 to 2024-05-03 - 48 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-03 07:30U:OCGNNews ReleaseOcugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
2024-05-02 07:16U:OCGNNews ReleaseOcugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
2024-04-29 06:45U:OCGNNews ReleaseOcugen Announces OCU400-Modifier Gene Therapy-Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
2024-04-26 09:05U:OCGNNews ReleaseUPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
2024-04-26 06:31U:OCGNNews ReleaseOcugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
2024-04-19 07:13U:OCGNNews ReleaseOcugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410-A Modifier Gene Therapy
2024-04-12 07:31U:OCGNNews ReleaseOcugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
2024-04-10 07:02U:OCGNNews ReleaseOcugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400-Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
2024-04-08 06:31U:OCGNNews ReleaseOcugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial - First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
2024-04-05 07:02U:OCGNNews ReleaseOcugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410-a Modifier Gene Therapy-in Phase 1/2 ArMaDa Study for Geographic Atrophy
2024-04-02 08:01U:OCGNNews ReleaseOcugen Provides Business Update with Certain Financials for the Year Ending 2023
2024-04-01 18:09U:OCGNNews ReleaseOcugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST-a Modifier Gene Therapy-in GARDian Study for Stargardt Disease
2024-04-01 17:44U:OCGNNews ReleaseOcugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
2024-03-18 06:31U:OCGNNews ReleaseOcugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
2024-03-13 08:01U:OCGNNews ReleaseOcugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
2024-03-06 07:30U:OCGNNews ReleaseOcugen to Present at Investing in Cures Summit
2024-02-28 08:00U:OCGNNews ReleaseOcugen Clinical Showcase Webcast Now Available
2024-02-26 08:30U:OCGNNews ReleaseOcugen Chairman and CEO to present at Abu Dhabi Family Office Summit
2024-02-22 16:05U:OCGNNews ReleaseOcugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
2024-02-21 16:05U:OCGNNews ReleaseOcugen to Present at 2024 BIO CEO & Investor Conference
2024-02-14 07:31U:OCGNNews ReleaseOcugen to Host Clinical Showcase in New York City on ‚  Wednesday, February 21, 2024
2024-01-31 08:00U:OCGNNews ReleaseOcugen to Present at Pharma Market Research Conference
2024-01-16 07:31U:OCGNNews ReleaseOcugen, Inc. Announces Bob Smith Joins Business Advisory Board
2023-12-21 06:30U:OCGNNews ReleaseOcugen Gains FDA Alignment on Key Aspects of OCU400 ¢ € ”Modifier Gene Therapy ¢ € ”Pivotal Phase 3 Study Design
2023-12-19 07:30U:OCGNNews ReleaseOcugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
2023-12-13 07:30U:OCGNNews ReleaseOcugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 ¢ € ”Modifier Gene Therapy ¢ € ”for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
2023-11-29 07:30U:OCGNNews ReleaseOcugen CEO to Present at NobleCon19 ¢ € “ Noble Capital Markets ¢ € ™ Nineteenth Annual Emerging Growth Equity Conference
2023-11-10 07:31U:OCGNNews ReleaseOcugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST ¢ € ”Modifier Gene Therapy ¢ € ”for Stargardt Disease
2023-11-09 06:30U:OCGNNews ReleaseOcugen Provides Business Update with Third Quarter 2023 Financial Results
2023-11-07 07:45U:OCGNNews ReleaseOcugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit
2023-11-02 07:30U:OCGNNews ReleaseOcugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results
2023-10-10 06:31U:OCGNNews ReleaseOcugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
2023-10-04 07:00U:OCGNNews ReleaseOcugen to Present at the 2023 Cell & Gene Meeting on the Mesa
2023-09-29 07:30U:OCGNNews ReleaseOcugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
2023-09-27 19:31U:OCGNNews ReleaseOcugen to Participate in Fireside Chat at Chardan ¢ € ™s 7th Annual Genetic Medicines Conference
2023-09-21 07:31U:OCGNNews ReleaseOcugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
2023-09-20 08:00U:OCGNNews ReleaseOcugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023
2023-09-13 08:15U:OCGNNews ReleaseOcugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
2023-09-12 19:30U:OCGNNews ReleaseOcugen to Host Virtual Investor & Analyst Event on September 13, 2023
2023-08-21 16:32U:OCGNNews ReleaseOcugen Provides Business Update with Second Quarter 2023 Financial Results
2023-08-18 16:39U:OCGNNews ReleaseOcugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results
2023-06-30 08:00U:OCGNNews ReleaseOcugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly
2023-06-09 16:05U:OCGNNews ReleaseOcugen, Inc. Announces Adjournment of Annual Meeting of Shareholders
2023-06-05 07:02U:OCGNNews ReleaseOcugen, Inc. Announces Business Advisory Board
2023-05-24 08:36U:OCGNNews ReleaseOcugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock
2023-05-23 16:01U:OCGNNews ReleaseOcugen, Inc. Announces Proposed Public Offering of Common Stock
2023-05-23 08:00U:OCGNNews ReleaseOcugen to Present at BIO International Convention 2023
2023-05-05 07:01U:OCGNNews ReleaseOcugen Provides Business Update with First Quarter 2023 Financial Results